Receptor News and Research

RSS

Researchers develop an integrated technology for seeing into cells at greater detail

Invading cells' private space - prying into their internal functions, decisions and communications - could be a powerful tool that may help researchers develop new immunotherapy treatment for cancer.

12 Aug 2020

Novel strategy provides new hope to fight COVID-19

A novel strategy has been developed by Novateur Ventures, which provides new hope in battle against COVID-19. The study titled 'A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes' was published in Frontiers in Pharmacology, a leading peer-reviewed journal.

12 Aug 2020

Researchers develop new strategies to treat osteoporosis

A research team from the National University of Singapore (NUS) has identified a new avenue to maintain bone health while reducing bone resorption.

12 Aug 2020

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

Study reveals new clues about SARS-CoV-2 infection

Working together, researchers at McMaster University and the University of Waterloo are searching for how the SARS-CoV-2 virus infects the lungs - and they're challenging what has become an accepted truth about the virus.

12 Aug 2020

New model predicts which COVID-19 patients are at higher risk for hospitalization

Cleveland Clinic researchers have developed and validated a risk prediction model (called a nomogram) that can help physicians predict which patients who have recently tested positive for SARS-CoV-2, the virus that causes COVID-19, are at greatest risk for hospitalization.

12 Aug 2020

Research looks at convalescent plasma use in COVID-19 mouse model

A new study by researchers at the University of Iowa and published on the preprint server bioRxiv in August 2020 reports the utility of a mouse model that recapitulates several aspects of human COVID-19 and can reflect the antiviral efficacy of new drugs as well.

12 Aug 2020

SARS-CoV-2 a "swarm" of mutant viruses

In this new study, the virus was serially passaged in independent cell types in a controlled environment. The researchers found that the virus rapidly adapts to the changing conditions in culture by selecting for pre-existing species.

12 Aug 2020

Scientist explains why COVID-19 targets only some organs while others are spared

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses the enzyme angiotensin-converting enzyme 2 (ACE2) to enter and infect human cells. It causes COVID-19 and can lead to a multitude of complications, including multi-organ impairment, partially due to the abundant expression of ACE2 in all human tissues.

11 Aug 2020

Researchers uncover a new vulnerability in the novel coronavirus' infamous spike protein

Northwestern University researchers have uncovered a new vulnerability in the novel coronavirus' infamous spike protein -- illuminating a relatively simple, potential treatment pathway.

11 Aug 2020

1st human data for Sinovac's SARS-CoV-2 CoronaVac vaccine is out

A group of Chinese researchers recently conducted a phase 2 clinical trial to further evaluate the immunogenicity and safety of SARS-CoV-2 inactivated vaccine known as CoronaVac. The results are currently available on the medRxiv preprint server and demonstrate that the vaccine is well tolerated and without any notable dose-related safety concerns, which opens the door for phase 3 clinical trial.

11 Aug 2020

Inhaled delivery of a potent neutralizing nanobody effective against SARS-CoV-2

A recent study by researchers from China, available on the bioRxiv preprint server, shows how stable neutralizing nanobody Nb11-59 might be a promising prophylactic and therapeutic molecule against coronavirus disease (COVID-19) – especially if administered via the inhalatory route.

11 Aug 2020

Research looks at how long SARS-CoV-2 antibodies last

A new study by researchers at the Fred Hutchinson Cancer Research Center and the University of Washington and published on the preprint server medRxiv* in August 2020 deals with the changes in neutralizing antibodies in the following months.

11 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

Novel coronavirus does not directly damage taste bud cells, UGA study shows

A new study from the Regenerative Bioscience Center at the University of Georgia is the first to suggest that COVID-19 does not directly damage taste bud cells.

10 Aug 2020

Researchers identify new treatment for osteoarthritis

The study results revolve around the long-established idea that machines within animal and human cells turn the sugars, fats, and proteins we eat into energy used by the body's millions of cells.

10 Aug 2020

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

FDA approves first companion diagnostic that uses liquid biopsy and NGS technology

Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor receptor (EGFR) gene in a deadly form of metastatic non-small cell lung cancer (NSCLC).

7 Aug 2020

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020